Lipocine Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Lipocine
LPCN Stock  USD 3.45  0.05  1.43%   
Lipocine financial statements provide useful quarterly and yearly information to potential Lipocine investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Lipocine financial statements helps investors assess Lipocine's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Lipocine's valuation are summarized below:
Gross Profit
7.9 M
Profit Margin
(0.51)
Market Capitalization
18.7 M
Enterprise Value Revenue
0.6167
Revenue
7.9 M
We have found one hundred twenty available fundamental ratios for Lipocine, which can be analyzed and compared to other ratios and to its peers in the industry. Self-guided Investors are advised to check Lipocine's last-minute fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 19th of March 2025, Market Cap is likely to drop to about 24.8 M. In addition to that, Enterprise Value is likely to drop to about 18.9 M

Lipocine Total Revenue

11.76 Million

Check Lipocine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lipocine's main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 5.8 M or Total Revenue of 11.8 M, as well as many indicators such as Price To Sales Ratio of 2.21, Dividend Yield of 0.0 or PTB Ratio of 1.3. Lipocine financial statements analysis is a perfect complement when working with Lipocine Valuation or Volatility modules.
  
Check out the analysis of Lipocine Correlation against competitors.
To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.

Lipocine Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets29.4 M22.5 M25.2 M
Slightly volatile
Other Current Liabilities1.5 M921.2 K1.3 M
Pretty Stable
Total Current Liabilities1.4 M1.5 M2.7 M
Slightly volatile
Other Liabilities196.5 K206.9 K3.1 M
Slightly volatile
Accounts Payable258.1 K271.7 K623.6 K
Slightly volatile
Cash8.9 M6.2 M10.3 M
Pretty Stable
Other Assets4 M3.8 M1.2 M
Slightly volatile
Cash And Short Term Investments26.4 M21.6 M22.6 M
Slightly volatile
Common Stock Total Equity10.7 K10.2 K4.3 K
Slightly volatile
Common Stock Shares Outstanding5.7 M5.4 M2.4 M
Slightly volatile
Liabilities And Stockholders Equity29.4 M22.5 M25.2 M
Slightly volatile
Other Current Assets653.9 K688.4 K1.2 M
Pretty Stable
Other Stockholder Equity154.4 M220.8 M132.5 M
Slightly volatile
Total Liabilities1.4 M1.5 M4 M
Slightly volatile
Total Current Assets28.5 M22.3 M24.5 M
Slightly volatile
Common Stock4.5 K8.9 K3.9 K
Slightly volatile
Property Plant Equipment124.4 K118.4 K69.2 K
Slightly volatile
Capital Surpluse143.4 M251 M133.4 M
Slightly volatile
Non Current Assets Total179.4 K188.8 K702.8 K
Slightly volatile
Property Plant And Equipment Gross1.6 M1.5 M525.3 K
Slightly volatile
Net Receivables44.7 K47 K334.7 K
Very volatile
Net Invested Capital27.8 M23.4 M22.6 M
Slightly volatile
Net Working Capital25.5 M23.3 M21.4 M
Slightly volatile
Short and Long Term Debt Total14.7 K15.4 K6.7 M
Slightly volatile
Long Term Debt Total4.3 M3.4 M5.6 M
Slightly volatile
Short and Long Term Debt2.5 M2.1 M3 M
Slightly volatile
Capital Stock7.2 K10.2 K4.6 K
Slightly volatile
Short Term Debt14.7 K15.4 K2.4 M
Slightly volatile
Current Deferred Revenue534.6 K288 K853.8 K
Slightly volatile
Non Current Liabilities Other1 M1.2 M1.3 M
Slightly volatile

Lipocine Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative5.8 M5 M5 M
Slightly volatile
Other Operating Expenses14.8 M12.4 M12.7 M
Slightly volatile
Research Development9 M7.4 M8 M
Slightly volatile
Cost Of Revenue9.4 M11.7 M8.6 M
Slightly volatile
Total Operating Expenses9.6 M12.4 M8.3 M
Slightly volatile
Non Recurring582.9 K655.8 K715 K
Slightly volatile
Tax Provision411613603
Slightly volatile
Reconciled Depreciation11.3 K20.9 K20.6 K
Slightly volatile
Interest Income1.6 M1.6 M378.4 K
Slightly volatile

Lipocine Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow9.8 M6.2 M11.3 M
Pretty Stable
Begin Period Cash Flow4.5 M4.8 M10.9 M
Very volatile
Stock Based Compensation388.1 K408.6 K1.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Average Payables645 K833.8 K768.8 K
Slightly volatile
Capex To Depreciation3.932.19168.035
Slightly volatile
Payables Turnover157176192
Slightly volatile
Average Inventory0.40.450.4906
Slightly volatile
Cash Per Share3.854.05219.781
Slightly volatile
Days Payables Outstanding1.491.681.8299
Slightly volatile
Income Quality1.10.651.3196
Pretty Stable
Current Ratio12.5314.753911.0151
Very volatile
Graham Number0.30.330.3649
Slightly volatile
Debt To Equity9.0E-40.0010.709
Slightly volatile
Capex Per Share0.03210.01690.0249
Slightly volatile
Average Receivables590.5 K409.5 K276.7 K
Pretty Stable
Interest Debt Per Share0.00360.00375.0775
Slightly volatile
Debt To Assets8.0E-49.0E-40.3162
Slightly volatile
Days Of Payables Outstanding1.491.681.8299
Slightly volatile
Long Term Debt To Capitalization0.140.150.3119
Slightly volatile
Total Debt To Capitalization9.0E-40.0010.3462
Slightly volatile
Debt Equity Ratio9.0E-40.0010.709
Slightly volatile
Quick Ratio12.3914.753910.896
Very volatile
Net Income Per E B T1.090.92460.9965
Slightly volatile
Cash Ratio6.364.10195.6392
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.151.0561
Slightly volatile
Debt Ratio8.0E-49.0E-40.3162
Slightly volatile
Gross Profit Margin0.560.630.6905
Slightly volatile

Lipocine Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap24.8 M26.1 M57.8 M
Slightly volatile
Enterprise Value18.9 M19.8 M40.8 M
Very volatile

Lipocine Fundamental Market Drivers

Cash And Short Term Investments21.6 M

Lipocine Upcoming Events

8th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
8th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Lipocine Financial Statements

Lipocine investors utilize fundamental indicators, such as revenue or net income, to predict how Lipocine Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue288 K534.6 K
Total Revenue11.2 M11.8 M
Cost Of Revenue11.7 M9.4 M
Stock Based Compensation To Revenue 0.04  0.03 
Sales General And Administrative To Revenue 0.45  0.42 
Research And Ddevelopement To Revenue 0.66  0.62 
Capex To Revenue 0.01  0.01 
Revenue Per Share 2.10  1.99 
Ebit Per Revenue(0.10)(0.11)
When determining whether Lipocine offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lipocine's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lipocine Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lipocine Stock:
How To Invest In Lipocine
Details
Is Lipocine Stock a good investment?
Details
What is Lipocine's Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Lipocine Correlation against competitors.
To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.75)
Revenue Per Share
1.486
Quarterly Revenue Growth
137.519
Return On Assets
(0.15)
Return On Equity
(0.20)
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipocine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY